Efficacy analysis of anti-migraine therapy for acute low-frequency hearing loss and investigation of its mechanisms.
10.13201/j.issn.2096-7993.2025.10.002
- Author:
Hongying LIN
1
;
Na ZHANG
2
;
Tongxiang DIAO
1
;
Lisheng YU
1
Author Information
1. Department of Otolaryngology Head and Neck Surgery，Peking University People's Hospital，Beijing，100044，China.
2. Department of Laboratory Medicine，Peking University People's Hospital.
- Publication Type:English Abstract
- Keywords:
acute low-frequency hearing loss;
migraine;
pathogenesis;
prognosis
- MeSH:
Humans;
Migraine Disorders/complications*;
Ginkgo biloba;
Male;
Female;
Flunarizine/therapeutic use*;
Plant Extracts/therapeutic use*;
Adult;
Treatment Outcome;
Middle Aged;
Ginkgo Extract
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2025;39(10):907-917
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics and prognostic factors of patients with acute low-frequency hearing loss（ALHL） and explore the potential role of migraine in its pathogenesis. Methods:A total of 56 ALHL patients treated at our outpatient clinic from June 2024 to January 2025 were randomly divided into two groups: a standardized treatment group and an anti-migraine treatment group. The standardized group received oral/intravenous steroids + oral/intravenous Ginkgo biloba extract, while the anti-migraine group received postauricular steroid injection/oral steroids + oral flunarizine for 2 weeks. Audiological, clinical, and psychological characteristics were collected, and statistical analysis was performed to assess clinical features and treatment outcomes, exploring the potential mechanism of migraine in ALHL. Results:The anti-migraine treatment group showed a significantly higher recovery rate than the standardized treatment group（92.86% vs 71.43%, P=0.036）. Among the anti-migraine group, 6 patients（21.43%） had a history of ALHL, 13（46.43%） had a confirmed migraine history, 26（92.86%） had anxiety, 26（92.86%） had depression, 5（17.86%） had irritable bowel syndrome, 21（75.00%） had sleep disorders, and 1（3.57%） experienced recurrence within 6 months. Conclusion:Anti-migraine therapy significantly improves the recovery rate in ALHL patients, suggesting that migraine may have a certain correlation with the pathogenesis of acute low-frequency hearing loss.
